Keros Therapeutics Inc (KROS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Keros Therapeutics Inc (KROS) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.25 Million) by net assets ($703.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KROS market cap overview for the company's overall valuation and market capitalisation.
Keros Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Keros Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Keros Therapeutics Inc ranked by their cash flow conversion efficiency. Explore KROS cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Resources Medical Holdings Company Limited
F:1PH
|
0.034x |
|
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas
SA:AGRO3
|
0.060x |
|
Jtekt India Limited
NSE:JTEKTINDIA
|
0.019x |
|
Braskem S.A.
SA:BRKM3
|
0.215x |
|
Fittech Co Ltd
TW:6706
|
0.016x |
|
NACL Industries Limited
NSE:NACLIND
|
-0.131x |
|
Crescent Capital BDC Inc
NASDAQ:CCAP
|
0.022x |
|
Jiangsu Xinning Modern Logist
SHE:300013
|
0.206x |
Annual Cash Flow Conversion Efficiency for Keros Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Keros Therapeutics Inc from 2018 to 2024. View latest Keros Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $571.55 Million | $-160.87 Million | -0.281x | +24.90% |
| 2023-12-31 | $332.21 Million | $-124.51 Million | -0.375x | -48.40% |
| 2022-12-31 | $277.42 Million | $-70.06 Million | -0.253x | +1.18% |
| 2021-12-31 | $243.17 Million | $-62.15 Million | -0.256x | -81.30% |
| 2020-12-31 | $261.72 Million | $-36.89 Million | -0.141x | +95.20% |
| 2019-12-31 | $5.45 Million | $-16.00 Million | -2.935x | -631.71% |
| 2018-12-31 | $12.76 Million | $7.04 Million | 0.552x | -- |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more